Answers are grounded in this paper and cite their sources.
Opioids are widely used in treatment of acute and chronic pain patients, and today a lot of efforts are put into individualize these therapies. Physicians would like to reduce deaths, minimize side effects and prevent toxicity, but – nevertheless PCA could represent a solution – up to date it is not yet completely reliable. A sustaining pharmacokinetic approach gives significant contribution, in particular in treatment of special populations (e.g. infants, elderly, and patients with renal/liver failure), which have a unique opioids pharmacokinetic profile to be taken into account, in order to maximize analgesic efficacy and reduce the risk of adverse events.
No takes yet. Share an insight, caveat, or question.
Gregori et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: